Gastric lymphoma: Difference between revisions
Mazia Fatima (talk | contribs) |
Ahmed Younes (talk | contribs) |
||
(44 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}}{{Mazia}} | {{CMG}}; {{AE}}{{Mazia}} | ||
==Overview== | ==Overview== | ||
Primary gastric lymphoma is [[Cancer (disease)|cancer]] [[derived]] from [[lymphocytes]] (a type of [[White blood cells|white blood cell]]) that originates in the [[stomach]]. Most common cause of primary gastric lymphoma is [[Mucosa-associated lymphoid tissue (MALT) lymphoma|mucosa-associated lymphoid tissue (MALT)]] [[lymphoma]] and [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL)]] of the [[stomach]]. Primary gastric lymphoma may be classified according to histology into MALT lymphoma and DLBCL. MALT lymphoma can be further divided into H. pylori positive MALT lymphoma and H. pylori negative MALT lymphoma. DLBCL can be divided into 3 subgroups germinal-center B-cell-like, activated B-cell-like, primary mediastinal DLBCL. The exact pathogenesis of primary gastric lymphoma is not fully understood. Common [[symptoms]] of primary gastric lymphoma include [[epigastric]] [[discomfort]], [[anorexia]], [[weight loss]], [[nausea]] associated with or without [[vomiting]], [[occult]] [[gastrointestinal bleeding]], [[early satiety]]. Less common [[symptoms]] include [[Fever|ever]] and [[night sweats]]. [[Patients]] with primary gastric lymphoma usually appear normal. Vital signs are within normal limits unless there is complication. [[Physical examination]] of [[patients]] with primary gastric lymphoma is usually remarkable for [[palpable]] [[mass]] and [[Lymphadenopathy|peripheral lymphadenopathy]]. Gastric lymphoma must be differentiated from conditions with similar presentation like [[acute gastritis]], [[Gastritis|chronic gastritis]], [[atrophic gastritis]], [[Crohn's disease]], [[gastroesophageal reflux disease]], [[peptic ulcer disease]], [[gastrinoma]] and [[gastric adenocarcinoma]]. Primary gastric lymphoma commonly affects [[elderly]] [[patients]] in the fifth or sixth decade of [[life]]. Primary gastric lymphoma is more [[Prevalence|prevalent]] in [[men]] than in [[women]]. [[Risk factors]] for gastric [[lymphoma]] include ''[[Helicobacter pylori]], l''ong-term [[immunosuppressant]] [[drug]] [[therapy]], [[HIV]] [[infection]]. The majority of [[patients]] with primary gastric lymphoma present with nonspecific [[symptoms]] in the 5th decade of life. Early [[clinical]] features include [[epigastric pain]], [[nausea]], and [[vomiting]]. If left untreated, patients with gastric lymphoma may progress to develop [[anorexia]], [[weight loss]], and [[early satiety]]. Common complications of gastric lymphoma include [[perforation]], [[hemorrhage]], and [[obstruction]]. [[Prognosis]] is generally good, and complete remission can be achieved after 6-8 rounds of [[chemotherapy]] or following [[surgery]]. [[Endoscopy|Upper gastrointestinal endoscopy]] with [[biopsy]] is the gold standard test for the [[diagnosis]] of [[gastric]] [[lymphoma]]. [[Laparotomy]] and [[laparoscopy]] should be performed when the [[patient]] presents with [[complications]] such as [[perforation]] or [[obstruction]]. An [[Endoscopic ultrasound|endoscopic ultrasound (EUS)]] will help assess the [[Depth of field|depth]] of [[lymphoma]] [[invasion]] and involvement of [[Lymph nodes|perigastric nodes]]. [[MALT lymphoma]] presents as [[superficial]] spreading or [[diffuse]] infiltrating [[lesion]] whereas [[diffuse]] [[Diffuse large B cell lymphoma|large B cell lymphoma]] has a [[Mass|typical mass]] forming [[lesion]] appearance on [[Endoscopy|endoscopic]] [[ultrasound]]. [[Imaging]] [[Investigational product|investigations]] including [[CT]] [[Scan|scans]] or [[endoscopic ultrasound]] are useful to stage [[disease]]. [[Hematological]] parameters are usually checked to assist with [[Staging (pathology)|staging]] and to exclude concomitant [[leukemia]]. An elevated [[lactate dehydrogenase|LDH]] level may be suggestive of [[lymphoma]]. There are no established measures for the [[Prevention (medical)|primary and secondary prevention]] of gastric lymphoma. | |||
Primary gastric lymphoma | ==Classification== | ||
Primary gastric lymphoma may be classified according to [[histology]] into the following subtypes: | |||
*B-cell lymphomas are of two main types: | |||
**[[MALT lymphoma]] | |||
**DLBCL ([[Diffuse large B cell lymphoma|diffuse large B-cell lymphoma]]) | |||
*[[MALT lymphoma]] can be further divided into: | |||
**[[Helicobacter pylori|H. pylori]] positive [[MALT lymphoma]] | |||
**[[Helicobacter pylori|H. pylori]] negative [[MALT lymphoma]] | |||
*[[Diffuse large B cell lymphoma|DLBCL]] can be divided into 3 subgroups based on the gene expression: | |||
**Germinal-center B-cell-like | |||
**Activated B-cell-like | |||
**Primary mediastinal DLBCL | |||
Most common cause of primary gastric lymphoma is [[Mucosa-associated lymphoid tissue (MALT) lymphoma|mucosa-associated lymphoid tissue (MALT)]] [[lymphoma]] and [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL)]] of the [[stomach]]. These account for 90% of all [[Diagnosis|diagnosed]] cases. [[Lymphomas]] originating outside the [[lymph nodes]] are referred to as [[Lymphoma|extra nodal lymphoma]]. Primary gastric lymphoma is the most common type of [[Lymphoma|extra nodal lymphoma]]. | ==Pathophysiology== | ||
*The exact pathogenesis of primary gastric lymphoma is not fully understood.<ref name="pmid8683376">{{cite journal |vauthors=Hussell T, Isaacson PG, Crabtree JE, Spencer J |title=Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue |journal=J. Pathol. |volume=178 |issue=2 |pages=122–7 |year=1996 |pmid=8683376 |doi=10.1002/(SICI)1096-9896(199602)178:2<122::AID-PATH486>3.0.CO;2-D |url=}}</ref><ref name="pmid20688564">{{cite journal |vauthors=Engels EA, Cho ER, Jee SH |title=Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study |journal=Lancet Oncol. |volume=11 |issue=9 |pages=827–34 |year=2010 |pmid=20688564 |pmc=2933963 |doi=10.1016/S1470-2045(10)70167-4 |url=}}</ref> | |||
*Primary gastric lymphoma is [[Cancer (disease)|cancer]] [[derived]] from [[lymphocytes]] (a type of [[White blood cells|white blood cell]]) that originates in the [[stomach]].<ref>Dawson IMP, Cornes JS, Morrison BC. Primary malignant lymphoid tumours of the intestinal tract. Br J Surg. 1961;49:80-89.</ref><ref>Aisenberg AC. Coherent view of non-Hodgkin's lymphoma. J Clin Oncol. 1995;13:2656-2675.</ref> | |||
*Most common cause of primary gastric lymphoma is [[Mucosa-associated lymphoid tissue (MALT) lymphoma|mucosa-associated lymphoid tissue (MALT)]] [[lymphoma]] and [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphoma (DLBCL)]] of the [[stomach]]. These account for 90% of all [[Diagnosis|diagnosed]] cases. [[Lymphomas]] originating outside the [[lymph nodes]] are referred to as [[Lymphoma|extra nodal lymphoma]]. Primary gastric lymphoma is the most common type of [[Lymphoma|extra nodal lymphoma]]. | |||
== | *Most of the [[MALT lymphoma|MALT lymphomas]] have an associated history of H.pylori infection. Chronic inflammation associated with H.pylori can cause T and B cell proliferation that increases the risk of malignant transformation. | ||
[[ | In case of [[Diffuse large B cell lymphoma|DLBCL]], antibiotic eradication therapy for H.pylori has shown to result in complete remission of lymphoma highlighting the role of H.pylori in the pathogenesis. | ||
*[[Hepatitis B virus|HBV]] plays a role in the pathogenesis of B-cell NHL, evidenced by an increased risk of developing [[Non-Hodgkin lymphoma|NHL]] in [[Hepatitis B surface antigen|HBsAg]] positive patients. | |||
===Histopathology=== | |||
Most of the gastric lymphomas are predominantly [[Non-Hodgkin lymphoma|non-Hodgkin’s lymphoma]] of [[B-cell|B-cell origin]]. Primary gastric lymphoma can vary from being well-differentiated, low-grade [[lymphomas]] to high grade or large cell [[lymphomas]].<ref name="pmid19565363">{{cite journal |vauthors=Wang T, Gui W, Shen Q |title=Primary gastrointestinal non-Hodgkin's lymphoma: clinicopathological and prognostic analysis |journal=Med. Oncol. |volume=27 |issue=3 |pages=661–6 |year=2010 |pmid=19565363 |doi=10.1007/s12032-009-9265-1 |url=}}</ref> | |||
==Symptoms== | |||
=====Common Symptoms===== | |||
=== | |||
==== | |||
Common [[symptoms]] of primary gastric lymphoma include:<ref name="pmid5007387">{{cite journal |vauthors=Freeman C, Berg JW, Cutler SJ |title=Occurrence and prognosis of extranodal lymphomas |journal=Cancer |volume=29 |issue=1 |pages=252–60 |year=1972 |pmid=5007387 |doi= |url=}}</ref><ref name="pmid11559724">{{cite journal |vauthors=Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rübe C, Probst A, Jaenke G, Bodenstein H, Junker A, Pott C, Schultze J, Heinecke A, Parwaresch R, Tiemann M |title=Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92 |journal=J. Clin. Oncol. |volume=19 |issue=18 |pages=3861–73 |year=2001 |pmid=11559724 |doi=10.1200/JCO.2001.19.18.3861 |url=}}</ref> | Common [[symptoms]] of primary gastric lymphoma include:<ref name="pmid5007387">{{cite journal |vauthors=Freeman C, Berg JW, Cutler SJ |title=Occurrence and prognosis of extranodal lymphomas |journal=Cancer |volume=29 |issue=1 |pages=252–60 |year=1972 |pmid=5007387 |doi= |url=}}</ref><ref name="pmid11559724">{{cite journal |vauthors=Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rübe C, Probst A, Jaenke G, Bodenstein H, Junker A, Pott C, Schultze J, Heinecke A, Parwaresch R, Tiemann M |title=Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92 |journal=J. Clin. Oncol. |volume=19 |issue=18 |pages=3861–73 |year=2001 |pmid=11559724 |doi=10.1200/JCO.2001.19.18.3861 |url=}}</ref> | ||
*[[Epigastric]] [[discomfort]] | *[[Epigastric]] [[discomfort]] | ||
Line 27: | Line 38: | ||
*[[Occult]] [[gastrointestinal bleeding]] | *[[Occult]] [[gastrointestinal bleeding]] | ||
*[[Early satiety]] | *[[Early satiety]] | ||
Less common [[symptoms]] include : | =====Less Common Symptoms===== | ||
Less common [[symptoms]] include: | |||
*[[Fever]] | *[[Fever]] | ||
*[[Night sweats]] | *[[Night sweats]] | ||
==== | ==Physical Examination== | ||
===Appearance of the Patient=== | |||
*[[Patients]] with primary gastric lymphoma usually appear normal.<ref name="pmid11559724">{{cite journal |vauthors=Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rübe C, Probst A, Jaenke G, Bodenstein H, Junker A, Pott C, Schultze J, Heinecke A, Parwaresch R, Tiemann M |title=Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92 |journal=J. Clin. Oncol. |volume=19 |issue=18 |pages=3861–73 |year=2001 |pmid=11559724 |doi=10.1200/JCO.2001.19.18.3861 |url=}}</ref> | *[[Patients]] with primary gastric lymphoma usually appear normal.<ref name="pmid11559724">{{cite journal |vauthors=Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rübe C, Probst A, Jaenke G, Bodenstein H, Junker A, Pott C, Schultze J, Heinecke A, Parwaresch R, Tiemann M |title=Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92 |journal=J. Clin. Oncol. |volume=19 |issue=18 |pages=3861–73 |year=2001 |pmid=11559724 |doi=10.1200/JCO.2001.19.18.3861 |url=}}</ref> | ||
===Vital signs=== | |||
Vital signs are within normal limits unless there is complication. | |||
===Abdominal Examination=== | |||
*[[Physical examination]] of [[patients]] with primary gastric lymphoma is usually remarkable for [[palpable]] [[mass]] and [[Lymphadenopathy|peripheral lymphadenopathy]]. | *[[Physical examination]] of [[patients]] with primary gastric lymphoma is usually remarkable for [[palpable]] [[mass]] and [[Lymphadenopathy|peripheral lymphadenopathy]]. | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
Line 95: | Line 91: | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | | +/- | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Line 124: | Line 120: | ||
|Food | |Food | ||
|[[Antacids]] | |[[Antacids]] | ||
| | | +/- | ||
| | | +/- | ||
| | | +/- | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | | +/- | ||
|[[Melena|Black stools]] | |[[Melena|Black stools]] | ||
| | | | ||
Line 147: | Line 143: | ||
|Food | |Food | ||
|[[Antacids]] | |[[Antacids]] | ||
| | | +/- | ||
| | | +/- | ||
| | | +/- | ||
| | | +/- | ||
| | | +/- | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|''[[H. pylori]] [[gastritis]]'' | |''[[H. pylori]] [[gastritis]]'' | ||
Line 168: | Line 164: | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | | +/- | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | |<nowiki>+/-</nowiki> | ||
| | | +/- | ||
| | | +/- | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|''[[H. pylori]]'' | |''[[H. pylori]]'' | ||
Line 195: | Line 191: | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | | +/- | ||
| | | +/- | ||
| | | | ||
* Chronic [[diarrhea]] often bloody with [[pus]] or [[mucus]] | * Chronic [[diarrhea]] often bloody with [[pus]] or [[mucus]] | ||
Line 229: | Line 225: | ||
* [[Antacids]] | * [[Antacids]] | ||
* Head elevation during sleep | * Head elevation during sleep | ||
| | | +/- | ||
(Suspect delayed gastric emptying) | (Suspect delayed gastric emptying) | ||
| | | +/- | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Line 258: | Line 254: | ||
* [[Radiation therapy]] | * [[Radiation therapy]] | ||
* Medications | * Medications | ||
* Zollinger- | * [[Zollinger-Ellison syndrome]] | ||
| | | | ||
* [[Epigastric pain]] sometimes extending to back | * [[Epigastric pain]] sometimes extending to back | ||
* [[Right upper quadrant pain]] | * [[Right upper quadrant pain]] | ||
| | |'''[[Duodenal ulcer]]''' | ||
*Pain aggravates with empty stomach | *Pain aggravates with empty stomach | ||
'''[[Gastric ulcer]]''' | '''[[Gastric ulcer]]''' | ||
Line 272: | Line 267: | ||
* [[Duodenal ulcer]] | * [[Duodenal ulcer]] | ||
:*Pain alleviates with food | :*Pain alleviates with food | ||
| | | +/- | ||
| | | +/- | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Line 299: | Line 294: | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | | +/- | ||
(suspect [[gastric outlet obstruction]]) | (suspect [[gastric outlet obstruction]]) | ||
| | | +/- | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Line 325: | Line 320: | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | | +/- | ||
| | | +/- | ||
| | | +/- | ||
| | | +/- | ||
| | | +/- | ||
| | | | ||
* [[Melena|Black stools]], or blood in stools | * [[Melena|Black stools]], or blood in stools | ||
Line 341: | Line 336: | ||
</div> | </div> | ||
==Demographics== | |||
* Primary gastric lymphoma commonly affects [[elderly]] [[patients]] in the fifth or sixth decade of [[life]].<ref>Thirlby RC. Gastrointestinal lymphoma: a surgical perspective. Oncology (Huntingt). 1993;7:29-32.</ref> | |||
* Primary gastric lymphoma is more [[Prevalence|prevalent]] in [[men]] than in [[women]]. | |||
==Risk Factors== | |||
[[Risk factors]] for gastric [[lymphoma]] include the following:<ref>[http://content.nejm.org/cgi/content/full/330/18/1267 NEJM article]</ref> | |||
*[[Helicobacter pylori]] | |||
*Long-term [[immunosuppressant]] [[drug]] [[therapy]] | |||
*[[HIV]] [[infection]] | |||
==Natural History, Complications and Prognosis== | |||
===Natural History=== | |||
*The majority of [[patients]] with primary gastric lymphoma present with nonspecific [[symptoms]] in the 5th decade of life. | |||
*Early [[clinical]] features include [[epigastric pain]], [[nausea]], and [[vomiting]]. | |||
*If left untreated, patients with gastric lymphoma may progress to develop [[anorexia]], [[weight loss]], and [[early satiety]]. | |||
===Complications=== | |||
*Common complications of gastric lymphoma include [[perforation]], [[hemorrhage]], and [[obstruction]]. | |||
===Prognosis=== | |||
*[[Prognosis]] is generally good, and complete remission can be achieved after 6-8 rounds of [[chemotherapy]] or following [[surgery]]. | |||
==Diagnosis== | |||
*[[Endoscopy|Upper gastrointestinal endoscopy]] with [[biopsy]] is the gold standard test for the [[diagnosis]] of [[gastric]] [[lymphoma]].<ref name="pmid1936785">{{cite journal |vauthors=Cogliatti SB, Schmid U, Schumacher U, Eckert F, Hansmann ML, Hedderich J, Takahashi H, Lennert K |title=Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients |journal=Gastroenterology |volume=101 |issue=5 |pages=1159–70 |year=1991 |pmid=1936785 |doi= |url=}}</ref><ref name="pmid7797116">{{cite journal |vauthors=Muller AF, Maloney A, Jenkins D, Dowling F, Smith P, Bessell EM, Toghill PJ |title=Primary gastric lymphoma in clinical practice 1973-1992 |journal=Gut |volume=36 |issue=5 |pages=679–83 |year=1995 |pmid=7797116 |pmc=1382669 |doi= |url=}}</ref><ref name="pmid19565363">{{cite journal |vauthors=Wang T, Gui W, Shen Q |title=Primary gastrointestinal non-Hodgkin's lymphoma: clinicopathological and prognostic analysis |journal=Med. Oncol. |volume=27 |issue=3 |pages=661–6 |year=2010 |pmid=19565363 |doi=10.1007/s12032-009-9265-1 |url=}}</ref> | |||
*[[Laparotomy]] and [[laparoscopy]] should be performed when the [[patient]] presents with [[complications]] such as [[perforation]] or [[obstruction]]. | |||
*Findings on [[Endoscopy|upper gastrointestinal endoscopy]] suggestive of [[gastric]] [[lymphoma]]: | |||
**[[Mucosal]] [[erythema]] | |||
**A [[mass]] or [[Polypoidy|polypoid]] [[Lesions|lesion]] with or without [[ulceration]] | |||
**[[Benign]]-appearing [[gastric]] [[ulcer]] | |||
**[[Nodular]] [[Lesions|lesion]] | |||
**Thickened, cerebroid [[gastric]] folds | |||
<br clear="left" />[[Image:Gastric MALT lymphoma 2.jpg|thumb|left|300px|Endoscopic image of gastric [[MALT lymphoma]] taken in body of [[stomach]] in patient who presented with [[upper gastrointestinal bleed|upper GI hemorrhage]]. Appearance is similar to [[gastric ulcer]] with adherent clot.|thumb|By Samir at the English language Wikipedia, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=4647530]]<br clear="left" /> | |||
*An [[Endoscopic ultrasound|endoscopic ultrasound (EUS)]] will help assess the [[Depth of field|depth]] of [[lymphoma]] [[invasion]] and involvement of [[Lymph nodes|perigastric nodes]]. | |||
*[[MALT lymphoma]] presents as [[superficial]] spreading or [[diffuse]] infiltrating [[lesion]] whereas [[diffuse]] [[Diffuse large B cell lymphoma|large B cell lymphoma]] has a [[Mass|typical mass]] forming [[lesion]] appearance on [[Endoscopy|endoscopic]] [[ultrasound]]. | |||
*[[Imaging]] [[Investigational product|investigations]] including [[CT]] [[Scan|scans]] or [[endoscopic ultrasound]] are useful to stage [[disease]]. | |||
*[[Hematological]] parameters are usually checked to assist with [[Staging (pathology)|staging]] and to exclude concomitant [[leukemia]]. An elevated [[lactate dehydrogenase|LDH]] level may be suggestive of [[lymphoma]]. | |||
===MRI=== | |||
Findings of Gastric lymphoma on MRI includes: | |||
*Irregularly thickened mucosal folds | |||
*Irregular submucosal infiltration | |||
*Annular constricting lesion | |||
*Exophytic tumor growth | |||
*Retroperitoneal [[lymphadenopathy]]. | |||
==Treatment== | ==Treatment== | ||
*The predominant [[therapy]] for [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphomas]] of the [[stomach]] is [[chemotherapy]]. | *The predominant [[therapy]] for [[Diffuse large B-cell lymphoma|diffuse large B-cell lymphomas]] of the [[stomach]] is [[chemotherapy]].<ref name="pmid19707443">{{cite journal |vauthors=Hauptrock B, Hess G |title=Rituximab in the treatment of non-Hodgkin's lymphoma |journal=Biologics |volume=2 |issue=4 |pages=619–33 |year=2008 |pmid=19707443 |pmc=2727901 |doi= |url=}}</ref><ref name="pmid17659705">{{cite journal |vauthors=Morgner A, Schmelz R, Thiede C, Stolte M, Miehlke S |title=Therapy of gastric mucosa associated lymphoid tissue lymphoma |journal=World J. Gastroenterol. |volume=13 |issue=26 |pages=3554–66 |year=2007 |pmid=17659705 |pmc=4146794 |doi= |url=}}</ref> | ||
*Second line [[therapy]] for [[MALT lymphoma|MALT lymphomas]] is usually [[chemotherapy]] with a single agent, and complete response rates of greater than 70% have been observed. | *Second line [[therapy]] for [[MALT lymphoma|MALT lymphomas]] is usually [[chemotherapy]] with a single agent, and complete response rates of greater than 70% have been observed. | ||
*[[Chemotherapy]] includes [[Treatments|treatment]] with [[CHOP]] with or without [[rituximab]]. | *[[Chemotherapy]] includes [[Treatments|treatment]] with [[CHOP]] with or without [[rituximab]]. | ||
Line 349: | Line 387: | ||
*Single drug [[chemotherapy]] is recommended as a second line therapy for [[MALT lymphoma|MALT lymphomas]] and is associated with a complete resolution of symptoms in greater than 70% cases. | *Single drug [[chemotherapy]] is recommended as a second line therapy for [[MALT lymphoma|MALT lymphomas]] and is associated with a complete resolution of symptoms in greater than 70% cases. | ||
*In case of complications like [[gastric outlet obstruction]], the recommended treatment is [[Gastrectomy|subtotal gastrectomy]] followed by post-operative. | *In case of complications like [[gastric outlet obstruction]], the recommended treatment is [[Gastrectomy|subtotal gastrectomy]] followed by post-operative. | ||
==Prevention== | |||
===Primary Prevention=== | |||
Proper treatment of [[Helicobacter pylori]], can prevent [[MALT lymphoma]]. | |||
===Secondary Prevention=== | |||
There are no established measures for the secondary prevention of gastric lymphoma. | |||
==References== | ==References== |
Latest revision as of 19:46, 7 February 2018
WikiDoc Resources for Gastric lymphoma |
Articles |
---|
Most recent articles on Gastric lymphoma Most cited articles on Gastric lymphoma |
Media |
Powerpoint slides on Gastric lymphoma |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Gastric lymphoma at Clinical Trials.gov Trial results on Gastric lymphoma Clinical Trials on Gastric lymphoma at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Gastric lymphoma NICE Guidance on Gastric lymphoma
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Gastric lymphoma Discussion groups on Gastric lymphoma Patient Handouts on Gastric lymphoma Directions to Hospitals Treating Gastric lymphoma Risk calculators and risk factors for Gastric lymphoma
|
Healthcare Provider Resources |
Causes & Risk Factors for Gastric lymphoma |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]
Overview
Primary gastric lymphoma is cancer derived from lymphocytes (a type of white blood cell) that originates in the stomach. Most common cause of primary gastric lymphoma is mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B-cell lymphoma (DLBCL) of the stomach. Primary gastric lymphoma may be classified according to histology into MALT lymphoma and DLBCL. MALT lymphoma can be further divided into H. pylori positive MALT lymphoma and H. pylori negative MALT lymphoma. DLBCL can be divided into 3 subgroups germinal-center B-cell-like, activated B-cell-like, primary mediastinal DLBCL. The exact pathogenesis of primary gastric lymphoma is not fully understood. Common symptoms of primary gastric lymphoma include epigastric discomfort, anorexia, weight loss, nausea associated with or without vomiting, occult gastrointestinal bleeding, early satiety. Less common symptoms include ever and night sweats. Patients with primary gastric lymphoma usually appear normal. Vital signs are within normal limits unless there is complication. Physical examination of patients with primary gastric lymphoma is usually remarkable for palpable mass and peripheral lymphadenopathy. Gastric lymphoma must be differentiated from conditions with similar presentation like acute gastritis, chronic gastritis, atrophic gastritis, Crohn's disease, gastroesophageal reflux disease, peptic ulcer disease, gastrinoma and gastric adenocarcinoma. Primary gastric lymphoma commonly affects elderly patients in the fifth or sixth decade of life. Primary gastric lymphoma is more prevalent in men than in women. Risk factors for gastric lymphoma include Helicobacter pylori, long-term immunosuppressant drug therapy, HIV infection. The majority of patients with primary gastric lymphoma present with nonspecific symptoms in the 5th decade of life. Early clinical features include epigastric pain, nausea, and vomiting. If left untreated, patients with gastric lymphoma may progress to develop anorexia, weight loss, and early satiety. Common complications of gastric lymphoma include perforation, hemorrhage, and obstruction. Prognosis is generally good, and complete remission can be achieved after 6-8 rounds of chemotherapy or following surgery. Upper gastrointestinal endoscopy with biopsy is the gold standard test for the diagnosis of gastric lymphoma. Laparotomy and laparoscopy should be performed when the patient presents with complications such as perforation or obstruction. An endoscopic ultrasound (EUS) will help assess the depth of lymphoma invasion and involvement of perigastric nodes. MALT lymphoma presents as superficial spreading or diffuse infiltrating lesion whereas diffuse large B cell lymphoma has a typical mass forming lesion appearance on endoscopic ultrasound. Imaging investigations including CT scans or endoscopic ultrasound are useful to stage disease. Hematological parameters are usually checked to assist with staging and to exclude concomitant leukemia. An elevated LDH level may be suggestive of lymphoma. There are no established measures for the primary and secondary prevention of gastric lymphoma.
Classification
Primary gastric lymphoma may be classified according to histology into the following subtypes:
- B-cell lymphomas are of two main types:
- MALT lymphoma can be further divided into:
- H. pylori positive MALT lymphoma
- H. pylori negative MALT lymphoma
- DLBCL can be divided into 3 subgroups based on the gene expression:
- Germinal-center B-cell-like
- Activated B-cell-like
- Primary mediastinal DLBCL
Pathophysiology
- The exact pathogenesis of primary gastric lymphoma is not fully understood.[1][2]
- Primary gastric lymphoma is cancer derived from lymphocytes (a type of white blood cell) that originates in the stomach.[3][4]
- Most common cause of primary gastric lymphoma is mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B-cell lymphoma (DLBCL) of the stomach. These account for 90% of all diagnosed cases. Lymphomas originating outside the lymph nodes are referred to as extra nodal lymphoma. Primary gastric lymphoma is the most common type of extra nodal lymphoma.
- Most of the MALT lymphomas have an associated history of H.pylori infection. Chronic inflammation associated with H.pylori can cause T and B cell proliferation that increases the risk of malignant transformation.
In case of DLBCL, antibiotic eradication therapy for H.pylori has shown to result in complete remission of lymphoma highlighting the role of H.pylori in the pathogenesis.
- HBV plays a role in the pathogenesis of B-cell NHL, evidenced by an increased risk of developing NHL in HBsAg positive patients.
Histopathology
Most of the gastric lymphomas are predominantly non-Hodgkin’s lymphoma of B-cell origin. Primary gastric lymphoma can vary from being well-differentiated, low-grade lymphomas to high grade or large cell lymphomas.[5]
Symptoms
Common Symptoms
Common symptoms of primary gastric lymphoma include:[6][7]
- Epigastric discomfort
- Anorexia
- Weight loss
- Nausea associated with or without vomiting
- Occult gastrointestinal bleeding
- Early satiety
Less Common Symptoms
Less common symptoms include:
Physical Examination
Appearance of the Patient
Vital signs
Vital signs are within normal limits unless there is complication.
Abdominal Examination
- Physical examination of patients with primary gastric lymphoma is usually remarkable for palpable mass and peripheral lymphadenopathy.
Differential Diagnosis
Gastric lymphoma must be differentiated from conditions with similar presentation like acute gastritis, chronic gastritis, atrophic gastritis, Crohn's disease, gastroesophageal reflux disease, peptic ulcer disease, gastrinoma and gastric adenocarcinoma :[8][9][10][11][12][13][14][15][16]
Disease | Cause | Symptoms | Diagnosis | Other findings | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Pain | Nausea
& Vomiting |
Heartburn | Belching or
Bloating |
Weight loss | Loss of
Appetite |
Stools | Endoscopy findings | |||||
Location | Aggravating Factors | Alleviating Factors | ||||||||||
Primary gastric lymphoma |
|
- | - | - | - | - | +/- | - | - | Useful in collecting the tissue for biopsy | Other symptoms
| |
Acute gastritis |
|
Food | Antacids | +/- | +/- | +/- | - | +/- | Black stools | - | ||
Chronic gastritis |
|
Food | Antacids | +/- | +/- | +/- | +/- | +/- | - | H. pylori gastritis
Lymphocytic gastritis
|
- | |
Atrophic gastritis | Epigastric pain | - | - | +/- | - | +/- | +/- | +/- | - | H. pylori
|
Autoimmune gastritis diagnosis include:
| |
Crohn's disease | - | - | - | - | - | +/- | +/- |
|
|
|||
GERD |
|
|
|
+/-
(Suspect delayed gastric emptying) |
+/- | - | - | - | - |
|
Other symptoms:
Complications
| |
Peptic ulcer disease |
|
Duodenal ulcer
|
|
+/- | +/- | - | - | - | Gastric ulcers
Duodenal ulcers
|
Other diagnostic tests | ||
Gastrinoma |
|
- | - | +/-
(suspect gastric outlet obstruction) |
+/- | - | - | - | Useful in collecting the tissue for biopsy |
Diagnostic tests
| ||
Gastric Adenocarcinoma |
|
- | - | +/- | +/- | +/- | +/- | +/- |
|
Esophagogastroduodenoscopy
|
Other symptoms |
Demographics
- Primary gastric lymphoma commonly affects elderly patients in the fifth or sixth decade of life.[17]
Risk Factors
Risk factors for gastric lymphoma include the following:[18]
- Helicobacter pylori
- Long-term immunosuppressant drug therapy
- HIV infection
Natural History, Complications and Prognosis
Natural History
- The majority of patients with primary gastric lymphoma present with nonspecific symptoms in the 5th decade of life.
- Early clinical features include epigastric pain, nausea, and vomiting.
- If left untreated, patients with gastric lymphoma may progress to develop anorexia, weight loss, and early satiety.
Complications
- Common complications of gastric lymphoma include perforation, hemorrhage, and obstruction.
Prognosis
- Prognosis is generally good, and complete remission can be achieved after 6-8 rounds of chemotherapy or following surgery.
Diagnosis
- Upper gastrointestinal endoscopy with biopsy is the gold standard test for the diagnosis of gastric lymphoma.[19][20][5]
- Laparotomy and laparoscopy should be performed when the patient presents with complications such as perforation or obstruction.
- Findings on upper gastrointestinal endoscopy suggestive of gastric lymphoma:
- An endoscopic ultrasound (EUS) will help assess the depth of lymphoma invasion and involvement of perigastric nodes.
- MALT lymphoma presents as superficial spreading or diffuse infiltrating lesion whereas diffuse large B cell lymphoma has a typical mass forming lesion appearance on endoscopic ultrasound.
- Imaging investigations including CT scans or endoscopic ultrasound are useful to stage disease.
- Hematological parameters are usually checked to assist with staging and to exclude concomitant leukemia. An elevated LDH level may be suggestive of lymphoma.
MRI
Findings of Gastric lymphoma on MRI includes:
- Irregularly thickened mucosal folds
- Irregular submucosal infiltration
- Annular constricting lesion
- Exophytic tumor growth
- Retroperitoneal lymphadenopathy.
Treatment
- The predominant therapy for diffuse large B-cell lymphomas of the stomach is chemotherapy.[21][22]
- Second line therapy for MALT lymphomas is usually chemotherapy with a single agent, and complete response rates of greater than 70% have been observed.
- Chemotherapy includes treatment with CHOP with or without rituximab.
- The mainstay of therapy for MALT lymphomas is antibiotic treatment to eradicate H.pylori. Regression is seen in about 60% of cases with eradication therapy alone.
- Single drug chemotherapy is recommended as a second line therapy for MALT lymphomas and is associated with a complete resolution of symptoms in greater than 70% cases.
- In case of complications like gastric outlet obstruction, the recommended treatment is subtotal gastrectomy followed by post-operative.
Prevention
Primary Prevention
Proper treatment of Helicobacter pylori, can prevent MALT lymphoma.
Secondary Prevention
There are no established measures for the secondary prevention of gastric lymphoma.
References
- ↑ Hussell T, Isaacson PG, Crabtree JE, Spencer J (1996). "Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue". J. Pathol. 178 (2): 122–7. doi:10.1002/(SICI)1096-9896(199602)178:2<122::AID-PATH486>3.0.CO;2-D. PMID 8683376.
- ↑ Engels EA, Cho ER, Jee SH (2010). "Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study". Lancet Oncol. 11 (9): 827–34. doi:10.1016/S1470-2045(10)70167-4. PMC 2933963. PMID 20688564.
- ↑ Dawson IMP, Cornes JS, Morrison BC. Primary malignant lymphoid tumours of the intestinal tract. Br J Surg. 1961;49:80-89.
- ↑ Aisenberg AC. Coherent view of non-Hodgkin's lymphoma. J Clin Oncol. 1995;13:2656-2675.
- ↑ 5.0 5.1 Wang T, Gui W, Shen Q (2010). "Primary gastrointestinal non-Hodgkin's lymphoma: clinicopathological and prognostic analysis". Med. Oncol. 27 (3): 661–6. doi:10.1007/s12032-009-9265-1. PMID 19565363.
- ↑ Freeman C, Berg JW, Cutler SJ (1972). "Occurrence and prognosis of extranodal lymphomas". Cancer. 29 (1): 252–60. PMID 5007387.
- ↑ 7.0 7.1 Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rübe C, Probst A, Jaenke G, Bodenstein H, Junker A, Pott C, Schultze J, Heinecke A, Parwaresch R, Tiemann M (2001). "Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92". J. Clin. Oncol. 19 (18): 3861–73. doi:10.1200/JCO.2001.19.18.3861. PMID 11559724.
- ↑ Sugimachi K, Inokuchi K, Kuwano H, Ooiwa T (1984). "Acute gastritis clinically classified in accordance with data from both upper GI series and endoscopy". Scand J Gastroenterol. 19 (1): 31–7. PMID 6710074.
- ↑ Sipponen P, Maaroos HI (2015). "Chronic gastritis". Scand J Gastroenterol. 50 (6): 657–67. doi:10.3109/00365521.2015.1019918. PMC 4673514. PMID 25901896.
- ↑ Sartor RB (2006). "Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis". Nat Clin Pract Gastroenterol Hepatol. 3 (7): 390–407. doi:10.1038/ncpgasthep0528. PMID 16819502.
- ↑ Sipponen P (1989). "Atrophic gastritis as a premalignant condition". Ann Med. 21 (4): 287–90. PMID 2789799.
- ↑ Badillo R, Francis D (2014). "Diagnosis and treatment of gastroesophageal reflux disease". World J Gastrointest Pharmacol Ther. 5 (3): 105–12. doi:10.4292/wjgpt.v5.i3.105. PMC 4133436. PMID 25133039.
- ↑ Ramakrishnan K, Salinas RC (2007). "Peptic ulcer disease". Am Fam Physician. 76 (7): 1005–12. PMID 17956071.
- ↑ Banasch M, Schmitz F (2007). "Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors". Wien Klin Wochenschr. 119 (19–20): 573–8. doi:10.1007/s00508-007-0884-2. PMID 17985090.
- ↑ Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM (2005). "Gastric adenocarcinoma: review and considerations for future directions". Ann Surg. 241 (1): 27–39. PMC 1356843. PMID 15621988.
- ↑ Ghimire P, Wu GY, Zhu L (2011). "Primary gastrointestinal lymphoma". World J Gastroenterol. 17 (6): 697–707. doi:10.3748/wjg.v17.i6.697. PMC 3042647. PMID 21390139.
- ↑ Thirlby RC. Gastrointestinal lymphoma: a surgical perspective. Oncology (Huntingt). 1993;7:29-32.
- ↑ NEJM article
- ↑ Cogliatti SB, Schmid U, Schumacher U, Eckert F, Hansmann ML, Hedderich J, Takahashi H, Lennert K (1991). "Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients". Gastroenterology. 101 (5): 1159–70. PMID 1936785.
- ↑ Muller AF, Maloney A, Jenkins D, Dowling F, Smith P, Bessell EM, Toghill PJ (1995). "Primary gastric lymphoma in clinical practice 1973-1992". Gut. 36 (5): 679–83. PMC 1382669. PMID 7797116.
- ↑ Hauptrock B, Hess G (2008). "Rituximab in the treatment of non-Hodgkin's lymphoma". Biologics. 2 (4): 619–33. PMC 2727901. PMID 19707443.
- ↑ Morgner A, Schmelz R, Thiede C, Stolte M, Miehlke S (2007). "Therapy of gastric mucosa associated lymphoid tissue lymphoma". World J. Gastroenterol. 13 (26): 3554–66. PMC 4146794. PMID 17659705.